Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes.

Literature DB >> 20223458

The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes.

Shany Blum, Moshe Vardi, Nina S Levy, Rachel Miller-Lotan, Andrew P Levy.

Abstract

Entities: CellLine Chemical Disease Gene Species

Mesh：

Substances：
Haptoglobins
Vitamin E

Year: 2010 PMID： 20223458 PMCID： PMC2897919 DOI： 10.1016/j.atherosclerosis.2010.02.018

Source DB: PubMed Journal: Atherosclerosis ISSN： 0021-9150 Impact factor: 5.162

× No keyword cloud information.

28 in total

1. Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis?

Authors: Daniel Steinberg; Joseph L Witztum
Journal: Circulation Date: 2002-04-30 Impact factor: 29.690

2. Vitamin E supplementation and cardiovascular events in high-risk patients.

Authors: S Yusuf; G Dagenais; J Pogue; J Bosch; P Sleight
Journal: N Engl J Med Date: 2000-01-20 Impact factor: 91.245

3. Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: The Strong Heart Study.

Authors: Andrew P Levy; Irit Hochberg; Kathleen Jablonski; Helaine E Resnick; Elisa T Lee; Lyle Best; Barbara V Howard
Journal: J Am Coll Cardiol Date: 2002-12-04 Impact factor: 24.094

4. Haptoglobin phenotype and coronary artery collaterals in diabetic patients.

Authors: Irit Hochberg; Ariel Roguin; Eugenia Nikolsky; Patil V Chanderashekhar; Silviu Cohen; Andrew P Levy
Journal: Atherosclerosis Date: 2002-04 Impact factor: 5.162

5. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project.

Authors: G de Gaetano
Journal: Lancet Date: 2001-01-13 Impact factor: 79.321

6. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial.

Authors: David D Waters; Edwin L Alderman; Judith Hsia; Barbara V Howard; Frederick R Cobb; William J Rogers; Pamela Ouyang; Paul Thompson; Jean Claude Tardif; Lyall Higginson; Vera Bittner; Michael Steffes; David J Gordon; Michael Proschan; Naji Younes; Joel I Verter
Journal: JAMA Date: 2002-11-20 Impact factor: 56.272

7. Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype.

Authors: Shany Blum; Moshe Vardi; Jonathan B Brown; Allen Russell; Uzi Milman; Chen Shapira; Nina S Levy; Rachel Miller-Lotan; Rabea Asleh; Andrew P Levy
Journal: Pharmacogenomics Date: 2010-05 Impact factor: 2.533

8. Haptoglobin genotype is predictive of major adverse cardiac events in the 1-year period after percutaneous transluminal coronary angioplasty in individuals with diabetes.

Authors: Ariel Roguin; Werner Koch; Adnan Kastrati; Doron Aronson; Albert Schomig; Andrew P Levy
Journal: Diabetes Care Date: 2003-09 Impact factor: 19.112

9. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials.

Authors: Deepak P Vivekananthan; Marc S Penn; Shelly K Sapp; Amy Hsu; Eric J Topol
Journal: Lancet Date: 2003-06-14 Impact factor: 79.321

10. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

Authors:
Journal: Lancet Date: 2002-07-06 Impact factor: 79.321

24 in total

Review 1. Preeclampsia and diabetes.

Authors: Tracey L Weissgerber; Lanay M Mudd
Journal: Curr Diab Rep Date: 2015-03 Impact factor: 4.810

Review 2. The association of diabetes and dementia and possible implications for nondiabetic populations.

Authors: Ramit Ravona-Springer; Michal Schnaider-Beeri
Journal: Expert Rev Neurother Date: 2011-11 Impact factor: 4.618

3. Effect of vitamin E supplementation on HDL function by haptoglobin genotype in type 1 diabetes: results from the HapE randomized crossover pilot trial.

Authors: Tina Costacou; Andrew P Levy; Rachel G Miller; Janet Snell-Bergeon; Rabea Asleh; Dan Farbstein; Catherine E Fickley; Georgia Pambianco; Rona de la Vega; Rhobert W Evans; Trevor J Orchard
Journal: Acta Diabetol Date: 2015-05-24 Impact factor: 4.280

Review 4. Is it time to screen for the haptoglobin genotype to assess the cardiovascular risk profile and vitamin E therapy responsiveness in patients with diabetes?

Authors: Moshe Vardi; Andrew P Levy
Journal: Curr Diab Rep Date: 2012-06 Impact factor: 4.810

Review 5. Haptoglobin genotype and its role in diabetic cardiovascular disease.

Authors: Tina Costacou; Andrew P Levy
Journal: J Cardiovasc Transl Res Date: 2012-03-24 Impact factor: 4.132

6. Vitamin E therapy results in a reduction in HDL function in individuals with diabetes and the haptoglobin 2-1 genotype.

Authors: Dan Farbstein; Shany Blum; Mordechai Pollak; Roy Asaf; Hilla Lee Viener; Orit Lache; Rabea Asleh; Rachel Miller-Lotan; Ido Barkay; Michael Star; Avery Schwartz; Shiri Kalet-Littman; David Ozeri; Jacob Vaya; Hagai Tavori; Moshe Vardi; Arie Laor; Stephen E Bucher; Yefim Anbinder; Doron Moskovich; Nur Abbas; Netta Perry; Yishai Levy; Andrew P Levy
Journal: Atherosclerosis Date: 2011-06-13 Impact factor: 5.162

Review 7. Haptoglobin genotype and cardiovascular outcomes in diabetes mellitus - natural history of the disease and the effect of vitamin E treatment. Meta-analysis of the medical literature.

Authors: Moshe Vardi; Shany Blum; Andrew P Levy
Journal: Eur J Intern Med Date: 2012-05-14 Impact factor: 4.487